Source:
New York TimesThe Evidence Gap: Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise
By ELISABETH ROSENTHAL
Published: August 19, 2008In two years, cervical cancer has gone from obscure killer confined mostly to poor nations to the West’s disease of the moment.
...The lightning-fast transition from newly minted vaccine to must-have injection in the United States and Europe represents a triumph of what the manufacturers call education and their critics call marketing. The vaccines, which offer some protection against infection from sexually transmitted viruses, are far more expensive than earlier vaccines against other diseases — Gardasil’s list price is $360 for the three-dose series, and the total cost is typically $400 to nearly $1,000 with markup and office visits (and often only partially covered by health insurance).
...
...And why the sudden alarm in developed countries about cervical cancer, some experts ask. A major killer in the developing world, particularly Africa, where the vaccines are too expensive for use, cervical cancer is classified as very rare in the West because it is almost always preventable through regular Pap smears, which detect precancerous cells early enough for effective treatment. Indeed, because the vaccines prevent only 70 percent of cervical cancers, Pap smear screening must continue anyway.
“Merck lobbied every opinion leader, women’s group, medical society, politicians, and went directly to the people — it created a sense of panic that says you have to have this vaccine now,” said Dr. Diane Harper, a professor of medicine at Dartmouth Medical School. Dr. Harper was a principal investigator on the clinical trials of both Gardasil and Cervarix, and she spent 2006-7 on sabbatical at the World Health Organization developing plans for cervical cancer vaccine programs around the world.
“Because Merck was so aggressive, it went too fast,” Dr. Harper said. “I would have liked to see it go much slower.”
But with their high price, the vaccines are straining national and state health budgets as well as family pocketbooks. These
were the first vaccines approved for universal use in any age group that clearly cost the health system money rather than saved it, in contrast to less expensive shots, against measles and tetanus, for example, that pay for themselves by preventing costly diseases.
And remember the next paragraph when your doctor or nurse recommends this vaccine:Co-opting Doctors and Nurses
Girls and their families are by no means the only marketing target.
In 2006, hundreds of doctors and nurses were signed up as unofficial spokesmen for Gardasil, trained by Merck, provided with a multimedia presentation and paid $4,500 for each 50-minute talk, delivered over Merck-sponsored meals. Many were paid for attending Merck “advisory board” meetings to discuss the shots.
Read more:
http://www.nytimes.com/2008/08/20/health/policy/20vaccine.html?pagewanted=1&_r=1&ref=todayspaper&adxnnlx=1219248138-tRxh8gCmoR6tKDKetChDvA